ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial

Autor: Gareth Griffiths, Cathy Burton, John Radford, Fay Chinnery, Joshua Caddy, Laura Day, S. Barrans, Graham P. Collins, Andrew Davies, Peter Johnson, Katy Mercer, Diana Fernando, Andrew McMillan, Simon Rule, Kirit M. Ardeshna

Publikováno v: Mercer, K, Davies, A, Barrans, S, Burton, C, Caddy, J, Chinnery, F, Day, L, Fernando, D, Ardeshna, K, Collins, G, Radford, J, Rule, S, McMillan, A, Johnson, P & Griffiths, G 2020, ' ACCEPT-combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL) : Study protocol for a Phase Ib/II open-label non-randomised clinical trial ', F1000Research, vol. 9, 941 . https://doi.org/10.12688/f1000research.22318.1
F1000Research

Background: Over 13,000 new cases of non-Hodgkin’s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d47c8f3bd5bb98c8b8428cb607c37a6
https://eprints.soton.ac.uk/443304/

MOLECULAR SUBCLUSTERS OF FOLLICULAR LYMPHOMA: A REPORT FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK

Autor: P. Beer, Eve Roman, S. van Hoppe, Stuart E. Lacy, Simon Crouch, R. Tooze, Alexandra Smith, Susanna L. Cooke, S. Barrans, Daniel Painter, Cathy Burton, Peter J. Campbell, Nichola Webster, Daniel J. Hodson, P. Glover, Russell Patmore

Publikováno v: Hematological Oncology. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0bf82ebb1c30006023ca9d0dd11cab9
https://doi.org/10.1002/hon.40_2879

Favourable Outcomes for High-Risk Diffuse Large B-Cell Lymphoma (IPI 3-5) Treated with Front-Line R-CODOX-M/R-IVAC Chemotherapy: Results of a Phase 2 UK NCRI Trial

Autor: S. Barrans, Ruth Pettengell, Elizabeth H Phillips, David C. Linch, Simon Rule, Laura Clifton-Hadley, Silvia Montoto, Amy A Kirkwood, Anthony Lawrie, Cathy Burton, Kirit M. Ardeshna, Andrew McMillan, Russell Patmore, Shankaranarayana Paneesha

Publikováno v: Phillips, E H 2020, ' Favourable Outcomes for High-Risk Diffuse Large B-Cell Lymphoma (IPI 3-5) Treated with Front-Line R-CODOX-M/R-IVAC Chemotherapy: Results of a Phase 2 UK NCRI Trial ', Annals of Oncology . https://doi.org/10.1016/j.annonc.2020.05.016
Annals of Oncology

Background Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e8fdb19968e61e842af25714095ebd
https://research.manchester.ac.uk/en/publications/695a6b4a-de4d-4c57-9d00-8ee63c59fe0f

Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality

Autor: Ming Wang, Moniek van Hoppe, Joe Sneath Thompson, Eguzkine Ochoa Ruiz, Josh Caddy, Debbie Hamid, Ming-Qing Du, Andrew Davies, Peter Johnson, Cathy Burton, S. Barrans, Francesco Cucco, Hannah Kennedy, Thomas Cummin, Alexandra Clipson

DNA samples from formalin-fixed paraffin-embedded tissues are highly degraded with variable quality, and this imposes a big challenge for targeted sequencing due to false positives, largely caused by PCR errors and cytosine deamination. To eliminate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::490e389754bdcccacad4091019e301c8
https://eprints.soton.ac.uk/424876/

HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS

Autor: Kerry L. Cox, Chulin Sha, P. Johnson, T. Murray, C. Burton, S. Barrans, Matthew J. Carter, Mark C Cragg, David R. Westhead, Thomas Cummin, Andrew Davies

Publikováno v: Hematological Oncology. 37:124-125

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9c4d0d1849cf401903903076151f493
https://doi.org/10.1002/hon.84_2629